上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2022 , Vol. 42 >Issue 12: 1745 - 1750

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.12.013

综述

乳腺癌合并新型冠状病毒肺炎感染患者的抗肿瘤合理化诊疗方案探讨

  • 张郁瑭 ,
  • 金奕婕 ,
  • 张凤春 ,
  • 徐迎春
展开
  • 1.上海交通大学医学院附属仁济医院肿瘤科，上海 200127
    2.上海交通大学医学院苏州九龙医院肿瘤科，苏州 215127
张郁瑭（1999—），男，本科生；电子信箱：553572892@qq.com。
徐迎春，电子信箱：xiaoxu2384@163.com。

收稿日期: 2022-06-24

  录用日期: 2022-09-04

  网络出版日期: 2022-12-28

基金资助

国家自然科学基金(81301858);苏州市科技计划项目(SYS201404);江苏省自然科学基金(BK20181186)

收起

Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19

  • Yutang ZHANG ,
  • Yijie JIN ,
  • Fengchun ZHANG ,
  • Yingchun XU
Expand
  • 1.Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215127, China
XU Yingchun, E-mail: xiaoxu2384@163.com.

Received date: 2022-06-24

  Accepted date: 2022-09-04

  Online published: 2022-12-28

Supported by

National Natural Science Foundation of China(81301858);Suzhou Science and Technology Project(SYS201404);Natural Science Foundation of Jiangsu Province(BK20181186)

Fold

摘要

新型冠状病毒肺炎（coronavirus disease 2019，COVID-19）作为一种新发的急性呼吸道传染病，目前已成为全球性重大公共卫生事件。在COVID-19流行期间，与健康人群相比，癌症患者因基础免疫力较差、年龄较大等特点，感染COVID-19后发生其他系统并发症的风险更高。研究显示，在女性恶性肿瘤中，乳腺癌的发病率位居第一。该类患者合并COVID-19感染的预后更差，且因COVID-19感染而不得不推迟抗肿瘤治疗。目前，关于推迟治疗对乳腺癌患者生存期的影响尚不明确，是否应调整这部分患者的治疗方案也仍处于研究中。该文通过系统回顾现有临床研究结果、各学会指南及专家共识，对COVID-19疫情下乳腺癌治疗方案的选择及合理化调整进行综述，探讨COVID-19感染的乳腺癌患者的抗肿瘤治疗时机和合理可行的抗肿瘤治疗方式。

关键词： 乳腺癌; 新型冠状病毒肺炎; 手术; 放射治疗; 系统治疗

本文引用格式

张郁瑭 , 金奕婕 , 张凤春 , 徐迎春 . 乳腺癌合并新型冠状病毒肺炎感染患者的抗肿瘤合理化诊疗方案探讨[J]. 上海交通大学学报（医学版）, 2022 , 42(12) : 1745 -1750 . DOI: 10.3969/j.issn.1674-8115.2022.12.013

Abstract

Coronavirus disease 2019 (COVID-19) has become a major global public health event as a new acute respiratory infectious disease. During the COVID-19 pandemic, compared with the healthy population, cancer patients had a higher risk of developing comorbidities of other systems, due to their bad poor immunity and older age. Research showed that breast cancer, as a malignant disease, had the highest disease incidence in female patients. Breast cancer patients with COVID-19 infection often have worse prognosis, and they have to postpone anti-tumor treatment due to COVID-19 infection. At present, the effect of delayed treatment on the survival rate of breast cancer patients is unclear, and whether the treatment plan of these patients should be adjusted is still being studied. Through the systematic review of existing clinical research studies, the guidelines of various societies and the expert consensus, this paper reviews the selection and rationalization of breast cancer treatment options under the COVID-19 epidemic, and discusses the opportunity and approaches of anti-tumor treatment for breast cancer patients infected with COVID-19.

Key words： breast cancer; coronavirus disease 2019 (COVID-19); surgery; radiotherapy; systemic therapy

参考文献

1 LIANG W H, GUAN W J, CHEN R C, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21(3): 335-337.
2 TIAN J, YUAN X, XIAO J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre,
3 YU J, OUYANG W, CHUA M L K, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China[J]. JAMA Oncol, 2020, 6(7): 1108-1110.
4 ZHANG L, ZHU F, XIE L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China[J]. Ann Oncol, 2020, 31(7): 894-901.
5 DAI M Y, LIU D B, LIU M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak[J]. Cancer Discov, 2020, 10(6): 783-791.
6 FOX T A, TROY-BARNES E, KIRKWOOD A A, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo-or immunotherapy[J]. Br J Haematol, 2020, 191(2): 194-206.
7 LEE L Y, CAZIER J B, ANGELIS V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study[J]. Lancet, 2020, 395(10241): 1919-1926.
8 PATHANIA A S, PRATHIPATI P, ABDUL B A, et al. COVID-19 and cancer comorbidity: therapeutic opportunities and challenges[J]. Theranostics, 2021, 11(2): 731-753.
9 JEE J, FOOTE M B, LUMISH M, et al. Chemotherapy and COVID-19 outcomes in patients with cancer[J]. J Clin Oncol, 2020, 38(30): 3538-3546.
10 ROBILOTTI E V, BABADY N E, MEAD P A, et al. Determinants of COVID-19 disease severity in patients with cancer[J]. Nat Med, 2020, 26(8): 1218-1223.
11 DE AZAMBUJA E, TRAPANI D, LOIBL S, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer[J]. ESMO Open, 2020, 5(Suppl 3): e000793.
12 黎立喜, 马飞. 《新型冠状病毒肺炎疫情期间乳腺癌合理化诊疗指南》解读[J]. 中国肿瘤临床, 2020, 47(8): 379-383.
12 LI L X, MA F. Interpretation of guidelines for the diagnosis and treatment of breast cancer during the COVID-19 outbreak[J]. Chin J Clin Oncol, 2020, 47(8): 379-383.
13 MARTA G N, POORTMANS P. Moderately hypofractionated breast radiation therapy: is more evidence needed? [J]. Lancet Oncol, 2019, 20(5): e226.
14 GRADISHAR W J, ANDERSON B O, ABRAHAM J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478.
15 WANG S L, FANG H, SONG Y W, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(3): 352-360.
16 CURIGLIANO G, BANERJEE S, CERVANTES A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus[J]. Ann Oncol, 2020, 31(10): 1320-1335.
17 SULLIVAN R J, JOHNSON D B, RINI B I, et al. COVID-19 and immune checkpoint inhibitors: initial considerations[J]. J Immunother Cancer, 2020, 8(1): e000933.
18 DEEKS J J, DINNES J, TAKWOINGI Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2[J]. Cochrane Database Syst Rev, 2020, 6(6): CD013652.
19 VAN KAMPEN J J A, VAN DE VIJVER D A M C, FRAAIJ P L A, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)[J]. Nat Commun, 2021, 12(1): 267.
20 RHEE C, KANJILAL S, BAKER M, et al. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? [J]. Clin Infect Dis, 2021, 72(8): 1467-1474.
21 BULLARD J, DUST K, FUNK D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples[J]. Clin Infect Dis, 2020, 71(10): 2663-2666.
22 YU K D, FAN L, QIU L X, et al. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent[J]. Oncotarget, 2017, 8(28): 46549-46556.
23 胡夕春, 胡志皇, 王碧芸, 等. 新型冠状病毒肺炎与抗肿瘤药物治疗[J]. 中国癌症杂志, 2022, 32(6): 499-511.
23 HU X C, HU Z H, WANG B Y, et al. COVID-19 and systemic anti-cancer therapy[J]. Chin Oncol, 2022, 32(6): 499-511.
24 WEI J L, WU M J, LIU J, et al. Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: a multi-center retrospective study in Hubei, China[J]. Breast, 2021, 59: 102-109.
25 BERSANELLI M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors[J]. Immunotherapy, 2020, 12(5): 269-273.
26 WU Q J, CHU Q, ZHANG H Y, et al. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors[J]. Cancer Commun (Lond), 2020, 40(8): 374-379.
27 LUO J, RIZVI H, EGGER J V, et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers[J]. Cancer Discov, 2020, 10(8): 1121-1128.
28 LIèVRE A, TURPIN A, RAY-COQUARD I, et al. Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)[J]. Eur J Cancer, 2020, 141: 62-81.
29 WANG B, HUANG Y. Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis[J]. Oncoimmunology, 2020, 9(1): 1824646.
30 DI GIACOMO A M, GAMBALE E, MONTERISI S, et al. SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: clinical course and outcome[J]. Eur J Cancer, 2020, 133: 1-3.
31 HU S Y, YIN F Y, NIE L T, et al. Estrogen and estrogen receptor modulators: potential therapeutic strategies for COVID-19 and breast cancer[J]. Front Endocrinol (Lausanne), 2022, 13: 829879.
32 SAINI K S, LANZA C, ROMANO M, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy[J]. Br J Cancer, 2020, 123(5): 694-697.
Options
文章导航

/

〈 〉